A randomised, double blind, placebo-controlled, parallel group trial of low-dose adjunctive alteplase during primary PCI
Reflections on No Reflow / Microvascular Obstruction

- **What does the patient bring?**
  Genome, comorbidities, behaviors

- **What prior & urgently applied therapies preceded reperfusion?**

- **What was the nature & timeliness of the reperfusion?**
T-Time Synopsis

- Well conducted 3 arm RCT to mitigate MVO: right pts, well balanced,…. stopped for futility
- Very timely D-B times ~24'… but total ischemic time ~ 147 min
- Short window for variable anti-platelet Rx*
- MVO occurred in ~ 44% pts & unaffected by either dose intracoronary tPA
- Similar frequency ~ 42% myocardial hemorrhage
- Large MI’s ~13% LV: no diff in size by MRI & ECG: moreover LVEF, LVESV, NT-proBNP all similar …. ? TnT
- No safety concerns
T-Time: Points to Ponder

- Unreliability ischemic time: Baseline Q
- 2-7 day MRI window: temporal variability
- Reperfusion sequencing: aspiration (30%), angioplasty, then tPA, stenting & later dilatation .... Modulators of primary outcome
- Adequacy & timing antiplatelet Rx

Addressing the MVO challenge going ......

- Heterogeneity mechanistic targets/confounders
- Better MVO taxonomy to provide more informed new solutions